Influence of body mass index and periprostatic fat on rectal dosimetry in permanent seed prostate brachytherapy
© Tiberi et al.; licensee BioMed Central Ltd. 2014
Received: 27 December 2013
Accepted: 5 April 2014
Published: 14 April 2014
We examined the influence of body mass index (BMI) and body fat distribution on rectal dose in patients treated with permanent seed brachytherapy for localized prostate cancer.
Methods and materials
We analyzed 213 patients treated with I125 seed brachytherapy for localized prostate cancer. BMI and rectal dosimetry data for all patients were available. Data on visceral and subcutaneous fat distribution at the level of the iliac crest (n = 140) as well as the distribution of periprostatic and subcutaneous fat at the symphysis pubis level were obtained (n = 117). Fat distribution was manually contoured on CT on day 30 after brachytherapy. The correlation between BMI, fat distribution and rectal dose (R100 (in cc), R150 (cc), D2 (Gy)) was analyzed using the Spearman correlation coefficient. Differences in rectal dose between tertiles of body fat distribution were calculated using nonparametric tests.
Periprostatic adipose was only weakly correlated with BMI (r = 0.0.245, p = 0.008) and only weakly correlated with the other fat measurements (r = 0.31-0.37, p < 0.001). On the other hand, BMI was correlated with all other fat measurements (≥0.58, p < 0.001). All the other fat measurements were strongly correlated with each other (r = 0.5-0.87, p < 0.001). Patients with an R100 of >1.3 cc (23% of patients) had less visceral fat (p = 0.004), less subcutaneous fat at the level of the iliac crest (p = 0.046) and a lower BMI (26.8 kg/m2 vs. 28.5 kg/m2, p = 0.02) than patients with an R100 of <1.3 cc. Results were very similar when comparing an R100 of >1.0 cc (34% of patients) across the tertiles. None of the tested linear regression models were predictive (max 12%) of dose to the rectum.
Dose to the rectum is dependent on BMI and body fat distribution. Periprostatic fat does not influence rectal dose. Dose to the rectum remains difficult to predict and depends on many factors, one of which is body fat distribution.
KeywordsProstate cancer Adipose tissue Body mass index Brachytherapy Rectal dose
Several studies have shown a dose-volume dependence on rectal bleeding after permanent seed brachytherapy (BT) [1–4]. Consequently, several European societies have published guidelines regarding the rectal dose .
Currently, little is known about the factors that might influence the dose to the rectum in BT. Some studies have shown that rectal dose decreases with the physician’s clinical experience  while others found no such effect. Certain groups  found that the dose to the rectum increased with prostate volume . Recently, Patil et al.  identified body mass index (BMI) as one of several factors that are negatively correlated with rectal dosimetry. It is clear that little consensus exists regarding which variables have an impact on the rectal dose in BT.
BMI has often been used as a surrogate for adipose tissue. We hypothesized that directly measuring adipose tissue distribution, especially around the prostate, would more accurately predict the dose to the rectum than using BMI alone.
Our cohort consisted of both low-risk patients (stage T1c-T2a, PSA level ≤10 ng/mL and Gleason score ≤6) and lower tier intermediate risk patients (T2b or PSA level 10-20 ng/mL or Gleason 7 in ≤30% of biopsies) as defined by the 2010 American Joint Committee on Cancer (AJCC) clinical stage guidelines . The patients had no history of prior hormonal therapy and were exclusively treated with permanent iodine-125 seed brachytherapy to 144Gy (BT) with an intraoperative planning system.
Adipose tissue measurements were available for patients who were part of two prior studies in our center investigating the influence of adipose tissue distribution on PSA bounce after BT [11, 12]. The BMI was calculated for all these patients. Height and weight data were obtained from preoperative records.
Adipose tissue distribution was measured on computed tomography (CT) scan images obtained 30 days following BT.
Most patients with fat measurements were part of two studies investigating the influence of fat distribution on PSA-bounce. However, only one study (n = 54)  included measurement of periprostatic fat in addition to the other measurements. The other study (n = 68)  measured most of the other fat distributions. We then randomly added other patients from our database that received permanent seed brachytherapy and measured their fat distribution and the BMI. All patients with fat measurements also had BMI data. BMI was available for 211 patients, perirpostatic fat in 116, subcutaneous fat at the symphysis level in 113 and at the iliac crest level in 136 patients and visceral fat in 139 patients.
All patients with fat measurements also had rectal dosimetry available. Rectal dosimetry was measured on CT scan images obtained 30 days following brachytherapy. The anterior rectum wall was contoured on all slices where prostate was visible. Dose-volume points analyzed were the volume in cubic centimeters of the anterior rectal wall receiving 100% and 150% of the prescribed dose (R100 and R150 in cc) and the isodose that encompassed 2% of the rectal volume (D2 in Gy). This retrospective analysis was approved by the institutional review board of the Centre Hospitalier de l’Université de Montréal (CHUM), approval number 12.240
The correlation between BMI, adipose tissue distribution, clinical factors and rectum dosimetry was analyzed using the Spearman correlation coefficient.
Differences in rectal dose between tertiles of body fat distribution were calculated using nonparametric tests, either the Kruskal Wallis or the Chi Square test when appropriate.
A linear regression was used for the multivariate analysis. Factors with a p < 0.1 in the correlation analysis were included in this multivariate analysis. All tests were two sided. Associations or differences of p <0.05 were deemed significant. All the data was analyzed using SPSS 20.0 for Windows (IBM SPSS, IBM Corp., Armonk, NY).
Clinical, implant and dosimetric characteristics
0.48/0.44 (range 0.32-0.68)
Prostate volume (cc)
Prostate V100 (%)
Prostate V150 (%)
Prostate D90 (Gy) <130 Gy
159.6/158.0 (26.3) 14.7%
Rectum R100 (cc)
Rectum R150 (cc)
Rectum D2 (Gy)
PSA (mg/mL) PSA <10 (mg/mL)
6.26/5.8 (3.3) 92%
T1 (AJCC 1997) T2
Correlation between body mass index (BMI) and adipose fat distribution
Correlation with BMI
Subcutaneous fat (iliac crest)
Subcutaneous fat (symphysis)
All body fat measurements were weakly (range correlation coeff. -0.19 to –0.29) but significantly (p = 0.02 to <0.001) inversely correlated with the dose to the rectum, except for periprostatic fat. (p = 0.38-0.83 for the D2, V100 and V150 of the rectum).
Rectum dosimetry according to tertiles of adipose tissue measurement
Subcut. fat (iliac crest)
Subcut. fat (symphysis)
<25 kg/m2 (n = 43)
25-30 kg/m2 (n = 98)
30-35 kg/m2 (n = 53)
>35 kg/m2 (n = 17)
Results were very similar when comparing an R100 of <1.0 cc across the tertiles of visceral fat (p = 0.02), subcutaneous fat at the level of the iliac crest (p = 0.01), periprostatic fat (p = 0.7) and subcutaneous fat at the symphysis level (p = 0.2).
Table 3 lists rectum dosimetry according to tertile of fat tissue measurement. Dosimetry to the rectum decreases significantly over all 3 tertiles for visceral fat, subcutaneous fat (iliac crest level) and the 4 BMI categories but not for periprostatic fat or subcutaneous fat (symphysis level).
Different linear regression models were then tested in a multivariate analysis to predict the dose to the rectum (R100, R150 and D2) as a continuous variable. Most models had a very small Adjusted R square value (max 0.12). Therefore these models have very little predictive (max 12%) value and we decided not to report them in this paper.
It is important to mention that none of the fat tissue measurements were correlated to prostate volume, age, Gleason score or prostate specific antigen (PSA). BMI was only weakly correlated to age (r = -0.16, p = 0.02).
Rectal bleeding following prostate brachytherapy occurs in less than 10% of patients [2, 14]. Known risk factors for rectal bleeding are the addition of EBRT , age  and dose to the rectum. Tran et al.  reported a much higher dose R100 for patients with rectal bleeding compared to patients without rectal bleeding (2.3 cc vs. 0.76 cc). Keyes et al.  found that patients without any rectal toxicity had a mean R100 of 0.96 cc while those with grade 1-2 rectal toxicity had an R100 ≥ 1.3 cc.
Physicians practicing brachytherapy realize that the dose to the rectum is very difficult to predict intraoperatively even though care is taken to keep it as low as possible. To our knowledge, this is the first report to measure adipose tissue distribution and its influence on rectum dosimetry. Our interest in this subject was awakened by our previous research investigating the influence of BMI and adipose tissue distribution on PSA-bounce [11, 16] and the findings of Patil et al. , which showed that a higher BMI was associated with a lower dose to the rectum. This finding is not surprising, as it seems intuitive that fatty tissue between the rectum and the prostate acts as a radiation buffer.
We can confirm that BMI in general and fat distribution have an influence on the dose to the rectum. We found that patients with a higher BMI and greater visceral and subcutaneous fat content at the iliac crest level have lower doses to the rectum. As the linear regression analysis found that the various fat measurements and BMI were only weakly predictive of the dose to the rectum, body fat remains only one of the many variables to consider. Rectal filling, another important factor influencing the rectal dose, was not measured in this study. As rectal filling can change from day to day, it is an unreliable variable affecting the dose to the rectum. One can argue that measuring the distance between the rectum and prostate at the time of seed implantation might be a better predictor of the rectal dose. We chose not to use this measurement as we feel this distance is dependent on how deep and at what angle the trans-rectal ultrasound (TRUS) probe is inserted.
Another factor to consider is the timing of the dosimetric evaluation, as it was have previously described that less prostatic edema leads to a higher dose .
We decided to directly measure adipose tissue in various regions and specifically around the prostate to see whether this would be a better predictor of dose to the rectum than the BMI. We expected the periprostatic fat to be predictive of dose to the rectum. Surprisingly, the periprostatic fat was the least correlated of all the fat measurements to the received rectal dose. A simple explanation may be that the adipose tissue between the rectum and prostate is compressed during the procedure. However, this compression is relieved by the time of the evaluation of the implant, 30 days after the procedure. At this point, the dose to the rectum should be lower for patients with a large fat pad. Patil et al.  and our present study are so far the first to report an influence of BMI on rectal dose in prostate brachytherapy. Their RV100 was very similar to ours with 0.79 cc but with a smaller standard deviation (0.49 versus 0.89). Interestingly, they reported a very similar mean BMI (27.8 kg/m2 ± 4.2) compared to our cohort (28.0 kg/m2 ± 4.5).
We also found that BMI was itself strongly correlated to all adipose tissue measurements except for periprostatic adipose tissue. Therefore, we believe that measurement of adipose tissue distribution has no advantage over measurement of the BMI to predict dose to the rectum.
We believe that investigation of the periprostatic adipose tissue is an interesting and nascent field. While exploring ways to measure the periprostatic adipose tissue and reviewing the literature, we realized the importance of guidelines in this new research field. Current practices for determining periprostatic adipose tissue vary greatly. One center mentioned that it used in-house automatic software, which included tissue in the levator ani sling . We believe that including the tissue within the sling induces a large bias as the volume depends largely on rectum filling. Bhindi et al.  used the diameter of the anterior fat pad as a surrogate, but there is also adipose tissue posterior and lateral to the prostate. Since part of this volume depends on rectum filling, we decided to include the anterior fat pad as well as the fat lateral and posterior to the prostate, but only outside of the levator ani sling.
Ribeiro et al. have shown an influence of periprostatic adipose tissue on prostate cancer aggressiveness in vitro . While all adipose tissue may produce soluble mediators, it may be the local mediators such as IL-6 regulated pathways released by the periprostatic adipose tissue that ultimately have an impact on prostate volume and prostate cancer pathogenesis .
Specific adipose tissue measurements are not superior to BMI in predicting dose to the rectum in permanent seed brachytherapy. Periprostatic adipose tissue is not predictive of dose to the rectum. We need to continue to identify potential factors that may predict the dose to the rectum.
- Herstein A, Wallner K, Merrick G, Mitsuyama H, Armstrong J, True L, Cavanagh W, Butler W: I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial. Cancer J 2005, 11: 385-389. 10.1097/00130404-200509000-00005View ArticlePubMedGoogle Scholar
- Keyes M, Spadinger I, Liu M, Pickles T, Pai H, Hayden A, Moravan V, Halperin R, McKenzie M, Kwan W, Agranovic A, Lapointe V, Morris WJ: Rectal toxicity and rectal dosimetry in low-dose-rate (125) I permanent prostate implants: a long-term study in 1006 patients. Brachytherapy 2012, 11: 199-208. 10.1016/j.brachy.2011.05.007View ArticlePubMedGoogle Scholar
- Snyder KM, Stock RG, Hong SML, Lo YC, Stone NN: Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001, 50: 335-341. 10.1016/S0360-3016(01)01442-0View ArticlePubMedGoogle Scholar
- Tran A, Wallner K, Merrick G, Seeberger J, Armstrong J, Mueller A, Cavanagh W, Lin D, Butler W: Rectal fistulas after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005, 63: 150-154. 10.1016/j.ijrobp.2005.01.021View ArticlePubMedGoogle Scholar
- Salembier C, Lavagnini P, Nickers P, Mangili P, Rijnders A, Polo A, Venselaar J, Hoskin P, GEC ESTRO PROBATE Group: Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 2007, 83: 3-10. 10.1016/j.radonc.2007.01.014View ArticlePubMedGoogle Scholar
- Le Fur E, Malhaire JP, Baverez D, Delage F, Perrouin-Verbe MA, Schlurmann F, Guerif S, Fournier G, Pradier O, Valeri A: Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer. Strahlenther Onkol 2012, 188: 1091-1095. 10.1007/s00066-012-0242-9View ArticlePubMedGoogle Scholar
- Rutten TP, Lawson JM, Marcu LG: Treatment technique evolution and dosimetry trends over seven years of low dose rate prostate brachytherapy at an Australian institution. Phys Med 2013, 29: 662-669. 10.1016/j.ejmp.2012.07.004View ArticlePubMedGoogle Scholar
- McNeely LK, Stone NN, Presser J, Chircus JH, Stock RG: Influence of prostate volume on dosimetry results in real-time 125I seed implantation. Int J Radiat Oncol Biol Phys 2004, 58: 292-299. 10.1016/S0360-3016(03)00783-1View ArticlePubMedGoogle Scholar
- Patil N, Crook J, Saibishkumar EP, Aneja M, Borj J, Pond G, Ma C: The effect of obesity on rectal dosimetry after permanent prostate brachytherapy. Brachytherapy 2009, 8: 218-222. 10.1016/j.brachy.2008.12.001View ArticlePubMedGoogle Scholar
- Beahrs OH, Henderson DE: Fourth edition of the manual for staging of cancer. Cancer 1992, 69: 2869. 10.1002/1097-0142(19920601)69:11<2869::AID-CNCR2820691140>3.0.CO;2-YView ArticleGoogle Scholar
- Chira C, Taussky D, Gruszczynski N, Meissner A, Larrivée S, Carrier JF, Donath D, Delouya G: Unusually high prostate-specific antigen bounce after prostate brachytherapy: Searching for etiologic factors. Brachytherapy 2013, 12: 603-607. 10.1016/j.brachy.2013.05.005View ArticlePubMedGoogle Scholar
- Delouya G, Taussky D, Ji CR, Sylvestre MP, Donath D: Relationship between prostate-specific antigen bounce body fat distribution and body mass index in permanent seed brachytherapy for prostate cancer. Brachytherapy 2012, 11: 214-218. 10.1016/j.brachy.2011.05.009View ArticlePubMedGoogle Scholar
- van Roermund JG, Bol GH, Witjes JA, Ruud Bosh JL, Kiemeney LA, van Vulpen M: Periprostatic fat measured on computed tomography as a marker for prostate cancer aggressiveness. World J Urol 2010, 28: 699-704. 10.1007/s00345-009-0497-7PubMed CentralView ArticlePubMedGoogle Scholar
- Buckstein M, Kerns S, Forysthe K, Stone NN, Stock RG: Temporal patterns of selected late toxicities in patients treated with brachytherapy or brachytherapy plus external beam radiation for prostate adenocarcinoma. BJU Int 2013, 111: E43-E47. 10.1111/j.1464-410X.2012.11436.xView ArticlePubMedGoogle Scholar
- Shiraishi Y, Hanada T, Ohashi T, Yorozu A, Toya K, Saito S, Shigematsu N: Novel parameter predicting grade 2 rectal bleeding after iodine-125 prostate brachytherapy combined with external beam radiation therapy. Int J Radiat Oncol Biol Phys 2013, 87: 182-187. 10.1016/j.ijrobp.2013.04.047View ArticlePubMedGoogle Scholar
- Bhindi B, Trottier G, Elharram M, Fernandes KA, Lockwood G, Toi A, Hersey KM, Finelli A, Evans A, van der Kwast TH, Fleshner NE: Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer. BJU Int 2012, 110: 980-986. 10.1111/j.1464-410X.2012.10957.xView ArticlePubMedGoogle Scholar
- Taussky D, Yeung I, Williams T, Pearson S, McLean M, Pond G, Crook J: Rectal-wall dose dependence on postplan timing after permanent-seed prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006, 65: 358-363. 10.1016/j.ijrobp.2005.12.024View ArticlePubMedGoogle Scholar
- Ribeiro R, Monteiro C, Cunha V, Oliveira MJ, Freitas M, Fraga A, Principe P, Lobato C, Lobo F, Morais A, Silva V, Sanches-Magalhäes J, Oliveira J, Pina F, Mota-Pinto A, Lopes C, Medeiros R: Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro. J Exp Clin Cancer Res 2012, 31: 32. 10.1186/1756-9966-31-32PubMed CentralView ArticlePubMedGoogle Scholar
- Finley DS, Calvert VS, Inokuchi J, Lau A, Narula N, Petricoin EF, Zaldivar F, Santos R, Tyson DR, Ornstein DK: Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol 2009, 182: 1621-1627. 10.1016/j.juro.2009.06.015View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.